{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:30:17Z","timestamp":1791009017088,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KI1006I"],"award-info":[{"award-number":["01KI1006I"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.antiviral.2013.04.008","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T14:35:34Z","timestamp":1366209334000},"page":"457-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Development of cellular signaling pathway inhibitors as new antivirals against influenza"],"prefix":"10.1016","volume":"98","author":[{"given":"Oliver","family":"Planz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.04.008_b0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.antiviral.2013.04.008_b0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.antiviral.2013.04.008_b0015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest."},{"key":"10.1016\/j.antiviral.2013.04.008_b0020","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0025","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.bmcl.2008.10.054","article-title":"The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901","volume":"18","author":"Barrett","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.04.008_b0030","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMra052211","article-title":"Avian influenza A (H5N1) infection in humans","volume":"353","author":"Beigel","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.04.008_b0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/SPC.0b013e3283090475","article-title":"New drugs in multiple myeloma","volume":"2","author":"Berenson","year":"2008","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.antiviral.2013.04.008_b0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.it.2004.03.008","article-title":"The two NF-kappaB activation pathways and their role in innate and adaptive immunity","volume":"25","author":"Bonizzi","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/138955711795049899","article-title":"Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside","volume":"11","author":"Bosco","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0540","unstructured":"Cao, B., Li, J., Mao, X., 2012. Dissecting bortezomib: development, application, adverse effects and future direction. Curr. Pharm. Des. 2012 Nov 2. [Epub ahead of print]."},{"key":"10.1016\/j.antiviral.2013.04.008_b0055","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/onc.2008.247","article-title":"The PTEN-PI3K pathway: of feedbacks and cross-talks","volume":"27","author":"Carracedo","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS interaction with PI3K: more than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.antiviral.2013.04.008_b0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1465-9921-6-135","article-title":"Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells","volume":"6","author":"Chan","year":"2005","journal-title":"Respir. Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0070","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/1078-0432.CCR-10-1102","article-title":"Dual inhibition of PI3K and mTORC1\/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia","volume":"16","author":"Chapuis","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.resp.2010.11.004","article-title":"Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm","volume":"175","author":"Cheng","year":"2011","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1074-7613(00)80146-6","article-title":"JNK2 and IKKbeta are required for activating the innate response to viral infection","volume":"11","author":"Chu","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2013.04.008_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2013.01.013","article-title":"A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies","author":"Cohen","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.antiviral.2013.04.008_b0090","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2013.04.008_b0095","first-page":"115","article-title":"NF-kappaB and innate immunity","volume":"349","author":"Dev","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antiviral Res.."},{"key":"10.1016\/j.antiviral.2013.04.008_b0105","doi-asserted-by":"crossref","first-page":"9439","DOI":"10.1128\/JVI.00533-10","article-title":"The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state","volume":"84","author":"Dudek","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0110","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1462-5822.2009.01309.x","article-title":"A new player in a deadly game: influenza viruses and the PI3K\/Akt signalling pathway","volume":"11","author":"Ehrhardt","year":"2009","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0115","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1462-5822.2006.00713.x","article-title":"Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence","volume":"8","author":"Ehrhardt","year":"2006","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0120","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1128\/JVI.02082-06","article-title":"Influenza A virus NS1 protein activates the PI3K\/Akt pathway to mediate antiapoptotic signaling responses","volume":"81","author":"Ehrhardt","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0545","doi-asserted-by":"crossref","unstructured":"Ehrhardt, C., Ruckle, A., Hrincius, E.R., Haasbach, E., Anhlan, D., Ahmann, K., Banning, C., Reiling, S.J., Kuhn, J., Strobl, S., Vitt, D., Leban, J., Planz, O., Ludwig, S., 2013. The NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance. Cell Microbiol. 2013 Jan 16. doi: 10.1111\/cmi.12108. [Epub ahead of print].","DOI":"10.1111\/cmi.12108"},{"key":"10.1016\/j.antiviral.2013.04.008_b0130","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1128\/MCB.01059-06","article-title":"Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-ras diffusion and signaling","volume":"26","author":"Eisenberg","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1083\/jcb.151.5.951","article-title":"Caspases disrupt the nuclear-cytoplasmic barrier","volume":"151","author":"Faleiro","year":"2000","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-8722-3-8","article-title":"From basic research to clinical development of MEK1\/2 inhibitors for cancer therapy","volume":"3","author":"Fremin","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0145","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1209954","article-title":"Introduction to NF-kappaB: players, pathways, perspectives","volume":"25","author":"Gilmore","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0150","first-page":"245","article-title":"Inhibition of NF-kappaB signaling as a strategy in disease therapy","volume":"349","author":"Gilmore","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0155","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1038\/sj.onc.1209982","article-title":"Inhibitors of NF-kappaB signaling: 785 and counting","volume":"25","author":"Gilmore","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0160","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2165\/00002018-200629120-00003","article-title":"Reye\u2019s syndrome: the case for a causal link with aspirin","volume":"29","author":"Glasgow","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.antiviral.2013.04.008_b0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0076-6879(99)00140-8","article-title":"Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome","volume":"300","author":"Grisham","year":"1999","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.antiviral.2011.07.006","article-title":"Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses","volume":"91","author":"Haasbach","year":"2011","journal-title":"Antiviral Res.."},{"key":"10.1016\/j.antiviral.2013.04.008_b0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.antiviral.2013.03.006","article-title":"Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro","volume":"98","author":"Haasbach","year":"2013","journal-title":"Antiviral Res.."},{"key":"10.1016\/j.antiviral.2013.04.008_b0180","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-09-1920","article-title":"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer","volume":"16","author":"Haura","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0185","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1038\/sj.onc.1209933","article-title":"Transcriptional regulation via the NF-kappaB signaling module","volume":"25","author":"Hoffmann","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0190","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.antiviral.2008.05.008","article-title":"Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity","volume":"80","author":"Hoffmann","year":"2008","journal-title":"Antiviral Res.."},{"key":"10.1016\/j.antiviral.2013.04.008_b0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.antiviral.2013.04.008_b0200","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1021\/jm00013a002","article-title":"Potent inhibitors of proteasome","volume":"38","author":"Iqbal","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0205","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"RDEA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK1\/2 for the treatment of cancer","volume":"69","author":"Iverson","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0210","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/gut.42.6.779","article-title":"Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors","volume":"42","author":"Jobin","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2013.04.008_b0215","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","article-title":"Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity","volume":"18","author":"Karin","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0225","doi-asserted-by":"crossref","first-page":"11236","DOI":"10.1073\/pnas.0801967105","article-title":"Apoptosis leads to a degradation of vital components of active nuclear transport and a dissociation of the nuclear lamina","volume":"105","author":"Kramer","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.04.008_b0230","doi-asserted-by":"crossref","first-page":"9880","DOI":"10.1128\/JVI.00909-08","article-title":"NF-kappaB signaling differentially regulates influenza virus RNA synthesis","volume":"82","author":"Kumar","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0235","first-page":"2463","article-title":"PI3 kinase inhibitors in the clinic: an update","volume":"32","author":"Kurtz","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.antiviral.2013.04.008_b0240","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1016\/j.bmcl.2007.08.022","article-title":"A novel class of potent NF-kappaB signaling inhibitors","volume":"17","author":"Leban","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.04.008_b0245","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"Lorusso","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkp161","article-title":"Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy","volume":"64","author":"Ludwig","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.04.008_b0255","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1515\/BC.2008.148","article-title":"Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy","volume":"389","author":"Ludwig","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0260","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1471-4914(02)00010-2","article-title":"Influenza-virus-induced signaling cascades: targets for antiviral therapy?","volume":"9","author":"Ludwig","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.antiviral.2013.04.008_b0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-5793(04)00108-5","article-title":"MEK inhibition impairs influenza B virus propagation without emergence of resistant variants","volume":"561","author":"Ludwig","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2013.04.008_b0270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1462-5822.2005.00678.x","article-title":"Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells","volume":"8","author":"Ludwig","year":"2006","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0275","doi-asserted-by":"crossref","first-page":"12419","DOI":"10.1128\/JVI.01219-10","article-title":"Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome","volume":"84","author":"Ma","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0280","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1158\/1078-0432.CCR-05-0081","article-title":"A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer","volume":"11","author":"Mackay","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0285","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1099\/vir.0.009050-0","article-title":"Influenza A virus proteins PB1 and NS1 are subject to functionally important phosphorylation by protein kinase C","volume":"90","author":"Mahmoudian","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0290","first-page":"209","article-title":"From the bench to the bed side: PI3K pathway inhibitors in clinical development","volume":"347","author":"Maira","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0295","doi-asserted-by":"crossref","first-page":"16707","DOI":"10.1074\/jbc.M510233200","article-title":"Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling","volume":"281","author":"Marjuki","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0300","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1743-422X-4-134","article-title":"Higher polymerase activity of a human influenza virus enhances activation of the hemagglutinin-induced Raf\/MEK\/ERK signal cascade","volume":"4","author":"Marjuki","year":"2007","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2013.04.008_b0305","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.1462-5822.2007.00902.x","article-title":"Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity","volume":"9","author":"Mazur","year":"2007","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0310","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/j.1462-5822.2009.01343.x","article-title":"Phosphorylation of the influenza A virus protein PB1-F2 by PKC is crucial for apoptosis promoting functions in monocytes","volume":"11","author":"Mitzner","year":"2009","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0315","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1046\/j.1365-2222.2003.01750.x","article-title":"Role of mitogen-activated protein kinases in influenza virus induction of prostaglandin E2 from arachidonic acid in bronchial epithelial cells","volume":"33","author":"Mizumura","year":"2003","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.antiviral.2013.04.008_b0320","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.smim.2010.04.010","article-title":"The TCR-mediated signaling pathways that control the direction of helper T cell differentiation","volume":"22","author":"Nakayama","year":"2010","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0325","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1099\/vir.0.79958-0","article-title":"Active NF-kappaB signalling is a prerequisite for influenza virus infection","volume":"85","author":"Nimmerjahn","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0330","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0335","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1038\/sj.onc.1207883","article-title":"Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice","volume":"23","author":"Olschlager","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0340","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002018-200225040-00001","article-title":"Is aspirin a cause of Reye\u2019s syndrome? A case against","volume":"25","author":"Orlowski","year":"2002","journal-title":"Drug Safety"},{"key":"10.1016\/j.antiviral.2013.04.008_b0345","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2013.04.008_b0350","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/JVI.77.10.5547-5556.2003","article-title":"Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant","volume":"77","author":"Ott","year":"2003","journal-title":"J. Virol"},{"key":"10.1016\/j.antiviral.2013.04.008_b0355","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","article-title":"Activators and target genes of Rel\/NF-kappaB transcription factors","volume":"18","author":"Pahl","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0360","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.04.008_b0365","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0370","doi-asserted-by":"crossref","first-page":"e1000196","DOI":"10.1371\/journal.ppat.1000196","article-title":"Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression","volume":"4","author":"Pauli","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.04.008_b0375","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1038\/sj.onc.1209937","article-title":"Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway","volume":"25","author":"Perkins","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0380","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2011.05.009","article-title":"Inhibition of influenza virus-induced NF-kappaB and Raf\/MEK\/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo","volume":"92","author":"Pinto","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0385","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1128\/JVI.75.10.4871-4877.2001","article-title":"MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells","volume":"75","author":"Planz","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0390","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1515\/BC.2008.145","article-title":"RNA viruses and the mitogenic Raf\/MEK\/ERK signal transduction cascade","volume":"389","author":"Pleschka","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0395","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0400","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.04.008_b0405","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0410","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.1128\/JVI.00323-12","article-title":"The NS1 protein of influenza A virus blocks RIG-I-mediated activation of the noncanonical NF-kappaB pathway and p52\/RelB-dependent gene expression in lung epithelial cells","volume":"86","author":"Ruckle","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/156800910790980250","article-title":"Bortezomib: a new pro-apoptotic agent in cancer treatment","volume":"10","author":"Russo","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.antiviral.2013.04.008_b0420","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.04.008_b0425","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1038\/sj.onc.1209934","article-title":"IkappaB kinase complexes: gateways to NF-kappaB activation and transcription","volume":"25","author":"Scheidereit","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2013.04.008_b0430","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.97.24.13057","article-title":"Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2","volume":"97","author":"Schubert","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.04.008_b0435","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.antiviral.2013.04.008_b0440","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.cr.7310019","article-title":"Antiviral innate immunity pathways","volume":"16","author":"Seth","year":"2006","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0445","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1006934612368","article-title":"Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production","volume":"199","author":"Shi","year":"1999","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0450","doi-asserted-by":"crossref","first-page":"12730","DOI":"10.1128\/JVI.01427-07","article-title":"SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K\/Akt signaling pathway activation","volume":"81","author":"Shin","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0455","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1099\/vir.0.82483-0","article-title":"Effect of the phosphatidylinositol 3-kinase\/Akt pathway on influenza A virus propagation","volume":"88","author":"Shin","year":"2007","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0460","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/JVI.77.1.460-469.2003","article-title":"Role of protein kinase C betaII in influenza virus entry via late endosomes","volume":"77","author":"Sieczkarski","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0465","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s12325-011-0072-7","article-title":"Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience","volume":"28","author":"Smith","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.antiviral.2013.04.008_b0470","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2146\/ajhp070272","article-title":"Bortezomib: a novel chemotherapeutic agent for hematologic malignancies","volume":"65","author":"Utecht","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.antiviral.2013.04.008_b0475","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","article-title":"Signalling by PI3K isoforms: insights from gene-targeted mice","volume":"30","author":"Vanhaesebroeck","year":"2005","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.antiviral.2013.04.008_b0480","doi-asserted-by":"crossref","first-page":"239368","DOI":"10.1155\/2012\/239368","article-title":"A key role for NF-kappaB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions","volume":"2012","author":"Visekruna","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0485","unstructured":"Wallace, E.M., Lyssikatos, J., Blake, J.F., Marlow, A., Greschuk, J., Yeh, T.C., Callejo, M., Marsh, V., Poch, G., Winkler, J.J., Koch, K., Davies, B.R., Wilkinson, R.W., Jones, D.C., Logie, A., McKay, J., Smith, P.D., Robinson, D.T., 2009. AZD8330 (ARRY-424704): Preclinical Evaluation of a Potent, Selective MEK 1\/2 Inhibitor Currently in Phase I Trails. AACR 100th Annual Meeting, Denver, USA, 18th\u201322nd April."},{"key":"10.1016\/j.antiviral.2013.04.008_b0490","doi-asserted-by":"crossref","first-page":"11678","DOI":"10.1074\/jbc.M513286200","article-title":"NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity","volume":"281","author":"Wei","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0495","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1128\/JVI.01048-10","article-title":"Inhibition of the ubiquitin-proteasome system affects influenza A virus infection at a postfusion step","volume":"84","author":"Widjaja","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0500","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1152\/physrev.1999.79.1.143","article-title":"Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human","volume":"79","author":"Widmann","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.antiviral.2013.04.008_b0505","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/emboj\/cdg279","article-title":"Caspase 3 activation is essential for efficient influenza virus propagation","volume":"22","author":"Wurzer","year":"2003","journal-title":"Embo. J."},{"key":"10.1016\/j.antiviral.2013.04.008_b0510","doi-asserted-by":"crossref","first-page":"30931","DOI":"10.1074\/jbc.M403258200","article-title":"NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas\/FasL is crucial for efficient influenza virus propagation","volume":"279","author":"Wurzer","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.04.008_b0515","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2013.04.008_b0520","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.04.008_b0555","first-page":"1","article-title":"Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Zeng","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.antiviral.2013.04.008_b0530","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s10495-007-0071-y","article-title":"Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling","volume":"12","author":"Zhirnov","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.antiviral.2013.04.008_b0535","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4161\/auto.5.3.7406","article-title":"Autophagy is involved in influenza A virus replication","volume":"5","author":"Zhou","year":"2009","journal-title":"Autophagy"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:26:03Z","timestamp":1759062363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0166354213000946"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.04.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of cellular signaling pathway inhibitors as new antivirals against influenza","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}